Advertisement

International Journal of Clinical Oncology

, Volume 11, Issue 6, pp 487–491 | Cite as

Resistance to gefitinib

  • Hidetaka Uramoto
  • Kenji SugioEmail author
  • Tsunehiro Oyama
  • Masakazu Sugaya
  • Takeshi Hanagiri
  • Kosei Yasumoto
CASE REPORT

Abstract

Subsets of patients with non-small cell lung cancer (NSCLC) who carry somatic mutations in the epidermal growth factor receptor (EGFR) have responded remarkably well to a tyrosine kinase inhibitor (TKI), gefitinib. Despite the dramatic response to this inhibitor, most patients nevertheless ultimately have a relapse. We herein report a case of advanced NSCLC in a patient carrying mutated EGFR (delE746-A750) who had a relapse after dramatic improvement by gefitinib treatment. The DNA sequence of the EGFR gene in a tumor biopsy specimen obtained from the relapse site revealed the presence of a second point mutation, resulting in a threonine-to-methionine amino acid substitution at position 790 of EGFR, which could not be detected in the tumor specimen taken before the treatment. Screening subjects with EGFR mutations therefore allows us to identify patients who can be successfully treated with gefitinib. Such observations should also help us in the search for more effective therapies against a specific subset of NSCLC.

Key words

EGFR TKI Gefitinib Mutation Lung cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parkin, DM, Bray, FI, Devesa, SS 2001Cancer burden in the year 2000. The global pictureEur J Cancer8466CrossRefGoogle Scholar
  2. 2.
    Rosell, R, Taron, M, Alberola, V,  et al. 2003Genetic testing for chemotherapy in non-small cell lung cancerLung Cancer197102CrossRefGoogle Scholar
  3. 3.
    Arteaga, CL 2003ErbB-targeted therapeutic approaches in human cancerExp Cell Res284122130PubMedCrossRefGoogle Scholar
  4. 4.
    Cohen, MH, Williams, GA, Sridhara, R,  et al. 2004United States Food and Drug Administration drug approval summary: gefitinib (ZD1839: Iressa): tabletsClin Cancer Res1012121218PubMedCrossRefGoogle Scholar
  5. 5.
    Mendelsohn, J, Baselga, J 2000The EGF receptor family as targets for cancer therapyOncogene1965506565PubMedCrossRefGoogle Scholar
  6. 6.
    Fukuoka, M, Yano, S, Giaccone, G,  et al. 2003Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancerJ Clin Oncol2122372246PubMedCrossRefGoogle Scholar
  7. 7.
    Kris, MG, Natale, RB, Herbst, RS,  et al. 2003Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialJAMA29021492158PubMedCrossRefGoogle Scholar
  8. 8.
    Miller, VA, Kris, MG, Shah, N,  et al. 2004Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancerJ Clin Oncol2211031109PubMedCrossRefGoogle Scholar
  9. 9.
    Lynch, TJ, Bell, DW, Sordella, R,  et al. 2004Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med35021292139PubMedCrossRefGoogle Scholar
  10. 10.
    Paez, JG, Janne, PA, Lee, JC,  et al. 2004EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience30414971500PubMedCrossRefGoogle Scholar
  11. 11.
    Pao, W, Miller, V, Zakowski, M,  et al. 2004EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A1011330613311PubMedCrossRefGoogle Scholar
  12. 12.
    Kosaka, T, Yatabe, Y, Endoh, H,  et al. 2004Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implicationsCancer Res6489198923PubMedCrossRefGoogle Scholar
  13. 13.
    Huang, SF, Liu, HP, Li, LH,  et al. 2004High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in TaiwanClin Cancer Res1081958203PubMedCrossRefGoogle Scholar
  14. 14.
    Han, SW, Kim, TY, Hwang, PG,  et al. 2005Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinibJ Clin Oncol1024932501CrossRefGoogle Scholar
  15. 15.
    Tokumo, M, Toyooka, S, Kiura, K,  et al. 2005The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancersClin Cancer Res1111671173PubMedGoogle Scholar
  16. 16.
    Mitsudomi, T, Kosaka, T, Endoh, H,  et al. 2005Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrenceJ Clin Oncol2325132520PubMedCrossRefGoogle Scholar
  17. 17.
    Uramoto, H, Sugio, K, Oyama, T,  et al. 2006Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in JapaneseLung Cancer517177PubMedCrossRefGoogle Scholar
  18. 18.
    Sugio, K, Uramoto, H, Ono, K,  et al. 2006Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smokingBr J Cancer94896903PubMedCrossRefGoogle Scholar
  19. 19.
    Kobayashi, S, Boggon, TJ, Dayaram, T,  et al. 2005EGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med352786792PubMedCrossRefGoogle Scholar
  20. 20.
    Pao, W, Miller, VA, Politi, KA,  et al. 2005Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med2111CrossRefGoogle Scholar
  21. 21.
    Wang, G, Reed, E, Li, QQ 2004Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancerOncol Rep5955965Google Scholar
  22. 22.
    Omuro, AM, Kris, MG, Miller, VA,  et al. 2005High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinibCancer10323442348PubMedCrossRefGoogle Scholar
  23. 23.
    Shigematsu, H, Lin, L, Takahashi, T,  et al. 2005Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ Natl Cancer Inst97339346PubMedCrossRefGoogle Scholar
  24. 24.
    Toyooka, S, Kiura, K, Mitsudomi, T 2005EGFR mutation and response of lung cancer to gefitinibN Engl J Med3522136PubMedCrossRefGoogle Scholar
  25. 25.
    Kwak, EL, Sordella, R, Bell, DW,  et al. 2005Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci U S A10276657670PubMedCrossRefGoogle Scholar
  26. 26.
    Kakiuchi, S, Daigo, Y, Ishikawa, N,  et al. 2004Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)Hum Mol Genet1330293043PubMedCrossRefGoogle Scholar
  27. 27.
    Okamoto, I, Kenyon, LC, Emlet, DR,  et al. 2003Expression of constitutively activated EGFRvIII in non-small cell lung cancerCancer Sci945056PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2006

Authors and Affiliations

  • Hidetaka Uramoto
    • 1
  • Kenji Sugio
    • 1
    Email author
  • Tsunehiro Oyama
    • 2
  • Masakazu Sugaya
    • 1
  • Takeshi Hanagiri
    • 1
  • Kosei Yasumoto
    • 1
  1. 1.Second Department of Surgery, School of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan
  2. 2.Department of Environmental Health, School of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan

Personalised recommendations